---
title: "Aziyo Biologics Earnings Call: Cash, Risk and 41X"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/278958379.md"
description: "Aziyo Biologics Earnings Call: Cash, Risk and 41X"
datetime: "2026-03-13T00:04:59.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/278958379.md)
  - [en](https://longbridge.com/en/news/278958379.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/278958379.md)
generator: "portal-rs"
---

# Aziyo Biologics Earnings Call: Cash, Risk and 41X

Aziyo Biologics Earnings Call: Cash, Risk and 41X

### Related Stocks

- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [CDMO.US](https://longbridge.com/en/quote/CDMO.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [ZBIO.US](https://longbridge.com/en/quote/ZBIO.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [ABCL.US](https://longbridge.com/en/quote/ABCL.US.md)

## Related News & Research

- [Abcellera director John S. Montalbano acquires common shares worth $110,300](https://longbridge.com/en/news/296260315.md)
- [Zenas BioPharma (ZBIO) Is Down 9.2% After Wider Losses And Leadership Changes - What's Changed](https://longbridge.com/en/news/295897113.md)
- [SBIO: U.S. Programmatic and EMEA drove 49% of Q2 sales, with margins rising to 61% and profitability expected in H2 2026](https://longbridge.com/en/news/296517769.md)
- [What's Going on With AbCellera Biologics Stock On Wednesday?](https://longbridge.com/en/news/295696830.md)
- [Zenas Biopharma posts corporate presentation on autoimmune disease pipeline, led by obexelimab program](https://longbridge.com/en/news/295789100.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**